MARCH2 prevents doxorubicin-induced cardiomyopathy by stabilizing NR1H2 and promoting clearance of apoptotic cardiomyocytes.

Summary

This mechanistic study identifies the MARCH2–NR1H2 (LXRβ) axis as central to cardiac macrophage efferocytosis in doxorubicin-induced cardiomyopathy. MARCH2 expression is reduced in cardiac macrophages from DiCM mice and human dilated cardiomyopathy patients; genetic ablation implicates loss of MARCH2 in impaired apoptotic cell clearance.

Key Findings

• Identified the MARCH2–NR1H2 (LXRβ) axis as a central regulator of cardiac macrophage efferocytosis in DiCM.
• Observed significantly reduced MARCH2 expression in cardiac macrophages from DiCM mice and human dilated cardiomyopathy patients.
• Genetic ablation of MARCH2 implicated loss of MARCH2 in impaired apoptotic cardiomyocyte clearance.

Clinical Implications

Targeting the MARCH2–NR1H2 axis could become a cardioprotective adjunct during anthracycline therapy, potentially reducing heart failure risk without compromising oncologic efficacy.

Limitations

• Preclinical mechanistic data; clinical efficacy of targeting MARCH2–NR1H2 remains untested.
• Abstract does not provide detailed outcomes or translational intervention data.

Future Directions

Validate MARCH2–NR1H2 modulation in large-animal models; develop small-molecule or gene-based strategies to augment efferocytosis; assess cardioprotection without impairing anti-tumor efficacy.